In the MD Anderson series of 98 patients with HER2-positive pT1a-b pN0 breast cancer, 5-year recurrence-free and distant recurrence-free survival rates were 77.1% and 86.4%, respectively [6]. This evidence concerns the gene ERBB2 and breast cancer.